Transurethral injections of autologous myoblasts and fibroblasts could relieve stress urinary incontinence in women, conclude authors of an Article published in this week’s edition of The Lancet.
And an accompanying comment hails the development as the beginning of a new era in urogynaecology.
Myoblasts are a type of muscle stem cell, while fibroblasts are cells which form the structural framework for many tissues in the body. Autologous cells are ones which the patient is the source of.
Dr Hannes Strasser, Medical University of Innsbruck, Austria, and colleagues studied 63 women with stress urinary incontinence, of which 42 were given myoblast/fibroblast injections and 21 were given conventional endoscopic injections of collagen. All the women were given incontinence scores from 0-6, based on a 24-hour voiding diary, 24-hour pad test and a patient questionnaire. After 12 months, the contractibility of the rhabadosphincter (the muscle responsible for contraction of the urethra) and the thickness of the urethra were analysed.
The researchers found that 38 of the 42 women given the autologous cell injections were completely continent after 12 months, compared with just two of the 21 patients given conventional collagen treatment. The mean thickness of the rhabadosphincter increased by 59% in patients given autologus cell injections, compared to a 9% increase in the collagen-injection group; and the contractibility of the rhabadosphincter increased by 268% in patients given the autologous cell injections, compared with 15% in the collagen-injected group. The change in thickness of the urethra did not differ significantly between the two groups.